PP
SLXP

Palladium Partners’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Palladium Partners’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-200
Closed -$21K – 520
2014
Q1 		$21K Buy
+200
New +$20.5K ﹤0.01% 423
2013
Q4 		– Sell
-200
Closed -$13K – 539
2013
Q3 		$13K Hold
200
– – ﹤0.01% 470
2013
Q2 		$13K Buy
+200
New +$11.4K ﹤0.01% 481

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Palladium Partners's SLXP Position: Q2 2014 in Review

Palladium Partners sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2014, closing a stake of 200 shares — an estimated $21K sold.

Palladium Partners first reported a position in SLXP in Q2 2013 and held it in 3 quarters. The position peaked at $21K in Q1 2014. 308 funds tracked by Wall St. Rank hold SLXP as of Q2 2014.

  • Palladium Partners reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2014 after selling out during the quarter.
  • Palladium Partners sold 200 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2014, an estimated $21K.
  • Palladium Partners first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 3 quarters.
  • Palladium Partners's SALIX PHARMACEUTICALS LTD DEL position peaked at $21K in Q1 2014.
  • 308 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2014.

Based on Palladium Partners's 13F filing for Q2 2014, filed 1 Aug 2014.